Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2022 | Using AI to predict light chain amyloidosis in patients with MGUS and SMM

Eli Muchtar • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Smoldering Myeloma

Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the potential of artificial intelligence (AI) in predicting the risk of developing AL amyloidosis in patients with multiple myeloma precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Eli Muchtar

Feasibility of double autologous stem cell transplantation in patients with AL amyloidosis
1:43
Feasibility of double autologous stem cell transplantation in patients with AL amyloidosis
Eli Muchtar • 6 Sep 2022
Incidence of hypovitaminosis D in patients with renal AL amyloidosis
1:02
Incidence of hypovitaminosis D in patients with renal AL amyloidosis
Eli Muchtar • 6 Sep 2022
Auto-HSCT in AL amyloidosis
6:10
Auto-HSCT in AL amyloidosis
Eli Muchtar • 9 Sep 2020
Localized amyloidosis: symptoms and site of disease
4:51
Localized amyloidosis: symptoms and site of disease
Eli Muchtar • 9 Sep 2020

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Eli Muchtar • 7 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Eli Muchtar • 8 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Eli Muchtar • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Eli Muchtar • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals